Alcoholic Hepatitis
71
9
12
35
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.2%
3 terminated out of 71 trials
92.1%
+5.6% vs benchmark
20%
14 trials in Phase 3/4
26%
9 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (71)
Intra-Hepatic Microbiota in Alcoholic Hepatitis
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
HA35 Moderate Alcoholic Hepatitis (AH) Study
Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis
A-TANGO Phase 2 Study
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Chronic Hepatitis B Virus Infection in Zambia
Short Course Steroids in Alcohol Associated Hepatitis
IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic Hepatitis Network Observational Study
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis